Search Press releases Keywords From To 24 Jan 2022 BIMZELX[®] (bimekizumab) Approved in Japan for the Treatment of Plaque Psoriasis, Generalized Pustular Psoriasis and Psoriatic Erythroderma Read More 21 Jan 2022 Disposals of own shares Read More 21 Jan 2022 Positive Top-Line Results for BIMZELX[®]▼(bimekizumab) in Second Phase 3 Psoriatic Arthritis Study Read More 19 Jan 2022 UCB to acquire Zogenix Read More 18 Jan 2022 Positive Top-Line Results for BIMZELX[®]▼(bimekizumab) in Phase 3 Non-Radiographic Axial Spondyloarthritis Study Read More 8 Jan 2022 Disposals of own shares Read More Pagination First page Previous page Previous … Page 36 Page 37 Page 38 Page 39 Current page 40 Page 41 Page 42 Page 43 Page 44 … Page 40 of 66 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
